secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001437749-25-025441
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma terminates AR101 asset purchase agreement; rights transferred to EnzCo
--------------------------------------------------------------------------------

- Company transferred all rights, title and interest in AR101 to EnzCo on August 5, 2025.
- Termination extinguishes all obligations under the April 21, 2021 asset purchase agreement with Rumpus.
- No penalties or remaining obligations for Aytu as a result of the termination.
- Clinical development of AR101 had been previously suspended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925025441/0001437749-25-025441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925025441/aytu20250617_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-025441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer